Advertisement

ARID1A, Prostaglandin E2, and Its Receptor as Possible Predictors of Malignant Transformation of the Endometrium in Endometriosis

  • A. S. Dyatlova
  • N. S. Lin’kovaEmail author
  • V. O. Polyakova
  • N. G. Samoshkin
  • I. M. Kvetnoi
EXPERIMENTAL METHODS FOR CLINICAL PRACTICE
  • 10 Downloads

We studied the expression of ARID1A, prostaglandin E2 synthase, and prostaglandin E2 receptor in the endometrium and ovarian, peritoneal, and intestinal endometrioid heterotopies in women with endometriosis of young and middle reproductive age. ARID1A protein is a tumor suppressor, its expression reduced in different types of cancer. Prostaglandin E2 synthase and prostaglandin E2 receptor are involved in the signaling cascade of inflammatory reactions presumably underlying the development of endometriosis. In endometrioid heterotopies, expression of ARID1A was reduced in 1.2-4.0 times, the expression of prostaglandin E2 synthase and prostaglandin E2 receptor was reduced in 2.9-5.2 times These findings suggest that ARID1A, prostaglandin E2 synthase, and prostaglandin E2 receptor can be used as predictors of malignant transformation of endometrioid heterotopies in women with endometriosis.

Key Words

endometriosis endometrioid heterotopies ARID1A prostaglandin E2 malignant transformation of the endometrium 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adamyan LV, Aznaurova YaB. Molecular aspects of endometriosis. Probl. Reprod. 2015;21(2):66-77. Russian.CrossRefGoogle Scholar
  2. 2.
    Bairamova NN, Protasova AE, Raskin GA, Vandeeva EN, Kuzmina NS, Yarmolinskaya MI, Orlova RV, Ovodenko DL. Endometrioid borderline ovarian tumor in the presence of endometriosis. Akush. Gin. 2018;(2):140-144. Russian.Google Scholar
  3. 3.
    Kachalina TS, Zinov’ev AN, Zinov’eva MS, Bogatova ME. Oncological aspects of genital endometriosis. Lech. Vrach. 2017;(5):61-66. Russian.Google Scholar
  4. 4.
    Shevchenko VE, Taipov MA, Kovalev SV, Arnotskaya NE, Pavlova OM, Kudryavtsev IA, Nikiforova ZN. Mapping of proteomic lysate of a MCF-7 cancer cell line for the identification of potential markers for breast cancer. Opukholi Zhen. Reprod. Systemy. 2012;(2):4-11. Russian.Google Scholar
  5. 5.
    Yukhno YeA, Trofimenko IA, Trufanov GYe. Malignant transformation of endometriosis: pearls and pitfalls at magnetic resonance imaging. Opukholi Zhen. Reprod. Systemy. 2013;(3-4):72-80. Russian.Google Scholar
  6. 6.
    Bedaiwy MA, Allaire C, Yong P, Alfaraj S. Medical management of endometriosis in patients with chronic pelvic pain. Semin. Reprod. Med. 2017;35(1):38-53.Google Scholar
  7. 7.
    Guan B, Mao TL, Panuganti PK, Kuhn E, Kurman RJ, Maeda D, Chen E, Jeng YM, Wang TL, Shih IeM. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am. J. Surg. Pathol. 2011;35(5):625-632.CrossRefGoogle Scholar
  8. 8.
    Guan B, Wang TL, Shih IeM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011;71(21):6718-6727.CrossRefGoogle Scholar
  9. 9.
    Paltsev MA, Polyakova VO, Kvetnoy IM, Anderson G, Kvetnaia TV, Linkova NS, Paltseva EM, Rubino R, De Cosmo S, De Cata A, Mazzoccoli G. Morphofunctional and signaling molecules overlap of the pineal gland and thymus: role and significance in aging. Oncotarget. 2016;7(11):11,972-11,983.Google Scholar
  10. 10.
    Rafique S, Decherney AH. Medical management of endometriosis. Clin. Obstet. Gynecol. 2017;60(3):485-496.CrossRefGoogle Scholar
  11. 11.
    Takeda T, Banno K, Okawa R, Yanokura M, Iijima M, Irie-Kunitomi H, Nakamura K, Iida M, Adachi M, Umene K, Nogami Y, Masuda K, Kobayashi Y, Tominaga E, Aoki D. ARID1A gene mutation in ovarian and endometrial cancers (Review). Oncol. Rep. 2016;35(2):607-613.CrossRefGoogle Scholar
  12. 12.
    Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih IeM, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 2010;363(16):1532-1543.CrossRefGoogle Scholar
  13. 13.
    Zhu J, Mayr D, Kuhn C, Mahner S, Jeschke U, von Schönfeldt V. Prostaglandin E2 receptor EP1 in healthy and diseased human endometrium. Histochem. Cell Biol. 2018;149(2):153-160.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • A. S. Dyatlova
    • 1
  • N. S. Lin’kova
    • 1
    • 2
    Email author
  • V. O. Polyakova
    • 1
    • 3
  • N. G. Samoshkin
    • 3
  • I. M. Kvetnoi
    • 1
    • 3
  1. 1.Department of BiogerontologyResearch Center St. Petersburg Institute of Bioregulation and GerontologySt. PetersburgRussia
  2. 2.Department of Therapy, Geriatrics, and Anti-Age Medicine, Academy of Postgraduate Education, Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical TechnologiesFederal Medical-Biological AgencyMoscowRussia
  3. 3.D. O. Ott Research Institute of ObstetricsGynecology, and Reproductive MedicineSt. PetersburgRussia

Personalised recommendations